Scholar Rock Holding Corporation $SRRK Shares Purchased by RA Capital Management L.P.

Key Points

• RA Capital Management L.P. increased its stake in Scholar Rock Holding Corporation by 6,351.3% in the first quarter, now holding over 1.1 million shares valued at approximately $36.5 million.
• Scholar Rock's stock has a current price of $32.65, down 1.9%, with a market cap of $3.14 billion and a price-to-earnings ratio of -11.22.
• Research analysts project that Scholar Rock will post an average EPS of -2.42 for the current year, with the stock receiving a consensus rating of "Buy".

RA Capital Management L.P. lifted its position in Scholar Rock Holding Corporation (NASDAQ:SRRK - Free Report) by 6,351.3% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,136,453 shares of the company's stock after purchasing an additional 1,118,837 shares during the quarter. Scholar Rock makes up 0.6% of RA Capital Management L.P.'s investment portfolio, making the stock its 29th biggest holding. RA Capital Management L.P. owned about 1.20% of Scholar Rock worth $36,537,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Lord Abbett & CO. LLC boosted its position in shares of Scholar Rock by 86.2% in the 1st quarter. Lord Abbett & CO. LLC now owns 877,374 shares of the company's stock valued at $28,207,000 after purchasing an additional 406,074 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Scholar Rock by 42.7% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 135,231 shares of the company's stock valued at $5,845,000 after purchasing an additional 40,436 shares during the period. Northern Trust Corp boosted its position in shares of Scholar Rock by 2.5% in the 1st quarter. Northern Trust Corp now owns 765,280 shares of the company's stock valued at $24,604,000 after purchasing an additional 18,753 shares during the period. GAMMA Investing LLC boosted its position in shares of Scholar Rock by 3,824.9% in the 1st quarter. GAMMA Investing LLC now owns 30,928 shares of the company's stock valued at $962,000 after purchasing an additional 30,140 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of Scholar Rock in the 1st quarter valued at about $12,775,000. 91.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Scholar Rock

In related news, Director Jeffrey S. Flier sold 20,316 shares of the firm's stock in a transaction that occurred on Monday, June 23rd. The stock was sold at an average price of $32.24, for a total value of $654,987.84. Following the completion of the transaction, the director directly owned 24,070 shares of the company's stock, valued at $776,016.80. This trade represents a 45.77% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Mo Qatanani sold 24,066 shares of the firm's stock in a transaction on Tuesday, July 8th. The stock was sold at an average price of $34.44, for a total value of $828,833.04. Following the transaction, the insider directly owned 115,495 shares of the company's stock, valued at $3,977,647.80. The trade was a 17.24% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 66,654 shares of company stock valued at $2,299,310 over the last ninety days. 13.30% of the stock is currently owned by company insiders.

Scholar Rock Stock Performance

Shares of SRRK stock traded down $1.03 during trading hours on Friday, reaching $31.41. 2,113,953 shares of the company's stock were exchanged, compared to its average volume of 1,712,805. The company has a market cap of $3.02 billion, a P/E ratio of -10.79 and a beta of 0.36. The company's 50 day moving average is $35.46 and its two-hundred day moving average is $33.46. Scholar Rock Holding Corporation has a 1 year low of $6.76 and a 1 year high of $46.98. The company has a debt-to-equity ratio of 0.21, a current ratio of 6.33 and a quick ratio of 6.33.

Scholar Rock (NASDAQ:SRRK - Get Free Report) last issued its earnings results on Wednesday, August 6th. The company reported ($0.98) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.66) by ($0.32). During the same period last year, the firm earned ($0.60) earnings per share. Equities research analysts anticipate that Scholar Rock Holding Corporation will post -2.42 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts recently issued reports on SRRK shares. Jefferies Financial Group began coverage on Scholar Rock in a research report on Thursday, August 21st. They issued a "buy" rating and a $50.00 target price for the company. BMO Capital Markets decreased their price objective on Scholar Rock from $57.00 to $45.00 and set an "outperform" rating for the company in a research report on Thursday, August 7th. Wedbush reaffirmed an "outperform" rating and set a $50.00 price objective on shares of Scholar Rock in a research report on Wednesday, June 18th. Cantor Fitzgerald began coverage on Scholar Rock in a research report on Thursday, July 17th. They set an "overweight" rating for the company. Finally, Lifesci Capital raised Scholar Rock to a "strong-buy" rating in a research report on Tuesday, June 3rd. Two investment analysts have rated the stock with a Strong Buy rating and eight have given a Buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Buy" and an average price target of $45.75.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.